术后眼内炎症:单次结膜下注射XG-102与地塞米松滴眼液的随机试验比较
这项多中心、随机、平行组、双盲、非劣效性临床试验纳入接受眼前后节联合手术、青光眼手术或复杂眼后节手术的患者,比较手术结束时单次结膜下注射XG-102(90 μg或900 μg)与安慰剂后分别配合安慰剂或地塞米松滴眼液每日4次共21天的效果。主要终点第28天前房细胞分级显示,XG-102 900 μg组与90 μg组对地塞米松均达到非劣效;XG-102 90 μg组与地塞米松组之间补救用药的差异有统计学意义(P = .013)。结论认为手术结束时单次结膜下注射XG-102对术后眼内炎症的疗效非劣效于地塞米松滴眼液。
要点
- 第28天前房细胞分级:XG-102 900 μg组与90 μg组对地塞米松均达到非劣效(P < .001与P = .003)。
- 补救用药比例:XG-102 90 μg组10例(21%)、XG-102 900 μg组7例(15%)、地塞米松组2例(4%)。
- 三组报告不良事件的患者数及事件性质相似。
核心结论
- 手术结束时单次结膜下注射XG-102在治疗术后眼内炎症方面非劣效于地塞米松滴眼液。
研究设计与样本
- 多中心、随机、平行组、双盲、非劣效性临床试验;患者接受眼前后节联合手术、青光眼手术或复杂眼后节手术。
- 手术结束时单次结膜下注射250 μL XG-102 90 μg(n = 47)、900 μg(n = 48)或安慰剂(n = 50),随后分别使用安慰剂、安慰剂或地塞米松滴眼液每日4次共21天。
- 主要终点为第28天前房细胞分级,比较XG-102 900 μg与地塞米松。
主要发现
- XG-102 900 μg组前房细胞分级对地塞米松的差值为-0.054(95%CI -0.350-0.242),非劣效性P < .001。
- XG-102 90 μg组前房细胞分级对地塞米松的差值为-0.086(95%CI -0.214-0.385),非劣效性P = .003。
- 补救用药:XG-102 90 μg组10例(21%)、XG-102 900 μg组7例(15%)、地塞米松组2例(4%);XG-102 90 μg组与地塞米松组的差异有统计学意义(P = .013)。
- 三组报告不良事件的患者数及事件性质相似。
关键数值与推荐
- 非劣效性判定:第28天前房细胞分级,XG-102 900 μg对地塞米松差值-0.054(95%CI -0.350-0.242),P < .001。
- 非劣效性判定:第28天前房细胞分级,XG-102 90 μg对地塞米松差值-0.086(95%CI -0.214-0.385),P = .003。
- 补救用药比例:XG-102 90 μg组10例(21%)、XG-102 900 μg组7例(15%)、地塞米松组2例(4%),XG-102 90 μg与地塞米松比较P = .013。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of XG-102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperative ocular inflammation. DESIGN: Multicenter, randomized, parallel group, double-masked, noninferiority clinical trial. METHODS: Patients who underwent anterior and posterior segments combined surgery or glaucoma surgery or complex posterior segment surgery were eligible to participate. Patients were administered a single subconjunctival injection of 250 μL XG-102 90 μg (n = 47) or 900 μg (n = 48) or placebo (n = 50) at the end of ocular surgery. Subconjunctival injection for each group (XG-102 90 μg, XG-102 900 μg, or placebo) was followed by eye drops instilled 4 times per day for 21 days with placebo, placebo, or dexamethasone solution, respectively. The primary outcome measure was anterior chamber cell grades at day 28 comparing XG-102 900 μg with dexamethasone. RESULTS: The anterior cell grades for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell grade [95% confidence interval -0.350-0.242]; P < .001 for noninferiority) for XG-102 900 μg and -0.086 anterior cell grade (95% confidence interval -0.214-0.385; P = .003 for noninferiority) for XG-102 90 μg. Rescue medication was introduced for 10 (21%), 7 (15%), and 2 (4%) patients allocated to the XG-102 90 μg, XG-102 900 μg, and dexamethasone groups, respectively. The difference between XG-102 90 μg and dexamethasone was statistically significant (P = .013). The number of patients for whom adverse events were reported and the nature of the events reported was similar between the 3 treatment groups. CONCLUSIONS: A single subconjunctival injection of XG-102 at the end of ocular surgery is noninferior to dexamethasone eye drops in the treatment of postoperative ocular inflammation.
引用
- Chiquet C, Aptel F, Creuzot-Garcher C, et al. Postoperative Ocular Inflammation: A Single Subconjunctival Injection of XG-102 Compared to Dexamethasone Drops in a Randomized Trial. Am J Ophthalmol. 2016. PMID: 27810317. doi:10.1016/j.ajo.2016.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。